WO1997047732A3 - Hexameric fusion proteins and uses therefor - Google Patents

Hexameric fusion proteins and uses therefor Download PDF

Info

Publication number
WO1997047732A3
WO1997047732A3 PCT/US1997/012599 US9712599W WO9747732A3 WO 1997047732 A3 WO1997047732 A3 WO 1997047732A3 US 9712599 W US9712599 W US 9712599W WO 9747732 A3 WO9747732 A3 WO 9747732A3
Authority
WO
WIPO (PCT)
Prior art keywords
fusion proteins
applications
uses therefor
binding
hexameric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/012599
Other languages
French (fr)
Other versions
WO1997047732A2 (en
Inventor
Margery Ann Chaikin
Sally Doreen Patricia Lyn
Raymond Whitney Sweet
Alemseged Truneh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Priority to AU38043/97A priority Critical patent/AU3804397A/en
Priority to JP10501910A priority patent/JP2000515731A/en
Priority to EP97935005A priority patent/EP0975355A2/en
Publication of WO1997047732A2 publication Critical patent/WO1997047732A2/en
Publication of WO1997047732A3 publication Critical patent/WO1997047732A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A hexameric fusion protein containing a dimeric binding protein provided with a tailpiece from an IgA antibody is described. This fusion protein is useful in therapeutics and vaccines, but is particularly well suited for applications for which the binding protein from which it is derived is unsatisfactory because of low binding affinity or for applications where multivalency is desired. These applications include diagnostics, binding assays and screening assays.
PCT/US1997/012599 1996-06-14 1997-06-13 Hexameric fusion proteins and uses therefor Ceased WO1997047732A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU38043/97A AU3804397A (en) 1996-06-14 1997-06-13 Hexameric fusion proteins and uses therefor
JP10501910A JP2000515731A (en) 1996-06-14 1997-06-13 Hexamer fusion proteins and uses thereof
EP97935005A EP0975355A2 (en) 1996-06-14 1997-06-13 Hexameric fusion proteins and uses therefor

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US1993496P 1996-06-14 1996-06-14
US60/019,934 1996-06-14
US4394897P 1997-02-19 1997-02-19
US60/043,948 1997-02-19
US3891597P 1997-02-21 1997-02-21
US60/038,915 1997-02-21

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09202346 A-371-Of-International 1999-01-13
US09/845,899 Continuation US20020147326A1 (en) 1996-06-14 2001-04-30 Hexameric fusion proteins and uses therefor

Publications (2)

Publication Number Publication Date
WO1997047732A2 WO1997047732A2 (en) 1997-12-18
WO1997047732A3 true WO1997047732A3 (en) 1998-01-29

Family

ID=27361321

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/012599 Ceased WO1997047732A2 (en) 1996-06-14 1997-06-13 Hexameric fusion proteins and uses therefor

Country Status (5)

Country Link
EP (1) EP0975355A2 (en)
JP (1) JP2000515731A (en)
AU (1) AU3804397A (en)
CA (1) CA2257861A1 (en)
WO (1) WO1997047732A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69840326D1 (en) * 1997-03-27 2009-01-22 Csl Ltd INCREASING IMMUNE RESPONSE USING TARGETED MOLECULES
US6475749B1 (en) * 1999-08-11 2002-11-05 The Regents Of The University Of California Rh hybrid antibody
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
US6875904B2 (en) 2000-09-20 2005-04-05 The Ohio State University Research Foundation Animal model for identifying agents that inhibit or enhance CTLA4 signaling
US7368114B2 (en) 2001-10-25 2008-05-06 The United States Of America As Represented By The Department Of Health And Human Services Fusion protein including of CD4
US7579437B2 (en) 2003-02-27 2009-08-25 Theravision Gmbh Polypeptides and methods for making the same
JP6228971B2 (en) * 2012-05-11 2017-11-08 メディミューン，エルエルシー CTLA-4 variant
BR112015000167B1 (en) * 2012-07-06 2021-11-23 Genmab B.V. DIMERIC PROTEIN, PROTEIN, COMPOSITION, KIT OF PARTS AND THEIR USES, AS WELL AS A METHOD TO INCREASE THE OLIGOMERIZATION IN SOLUTION OF A DIMERIC PROTEIN COMPRISING A FIRST AND SECOND POLYPEPTIDE, EACH COMPRISING AT LEAST ONE CH2 AND CH3 REGIONS HUMAN AND VARIANT DIMER PROTEIN
ES2758979T3 (en) * 2012-07-06 2020-05-07 Genmab Bv Dimeric protein with triple mutations
JP2017518965A (en) 2014-05-02 2017-07-13 モメンタ ファーマシューティカルズ インコーポレイテッ Compositions and methods related to engineered Fc constructs
AU2016246695A1 (en) 2015-04-07 2017-10-26 Genentech, Inc. Antigen binding complex having agonistic activity and methods of use
WO2017151971A2 (en) 2016-03-02 2017-09-08 Momenta Pharmaceuticals, Inc. METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
BR112018074056A2 (en) 2016-05-23 2019-03-06 Momenta Pharmaceuticals, Inc. compositions and methods related to manipulated fc constructs
CN110650748B (en) 2017-01-06 2024-01-02 动量制药公司 Compositions and methods related to engineered Fc constructs
KR20210083260A (en) * 2018-10-23 2021-07-06 아이쥐엠 바이오사이언스 인코포레이티드 Multivalent IgM- and IgA-Fc based binding molecules
US12589132B2 (en) 2019-02-22 2026-03-31 Five Prime Therapeutics, Inc. CD80 extracellular domain Fc fusion proteins for treating PD-L1 negative tumors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BLOOD, 15 November 1994, Volume 84, GUINAN et al., "Pivotal Role of the B7:CD28 Pathway in Transplantation Tolerance and Tumor Immunity", pages 3261-3282. *
INTERNATIONAL IMMUNOLOGY, 1996, Vol. 8, No. 1, YI-QUN et al., "Differential Requirements for Co-Stimulatory Signals from B7 Family Members by Resting Versus Recently Activated Memory T Cells Towards Soluble Recall Antigens", pages 37-44. *
J. IMMUNOL., 1995, Volume 154, SMITH et al., "Addition of a mu-Tailpiece to IgG Results in Polymeric Antibodies with Enhanced Effector Functions Including Complement-Mediated Cytolysis by IgG4", pages 2226-2236. *
J. IMMUNOL., 1996, Volume 156, SORENSEN et al., "Effect of the IgM and IgA Secretory Tailpieces on Polymerization and Secretion of IgM and IgG", pages 2858-2865. *
JOURNAL OF NEUROIMMUNOLOGY, 1996, Vol. 65, PERRIN et al., "Opposing Effects of CTLA4-Ig and Anti-CD80 (B7-1) plus Anti-CD86 (B7-2) on Experimental Allergic Encephalomyelitis", pages 31-39. *

Also Published As

Publication number Publication date
CA2257861A1 (en) 1997-12-18
JP2000515731A (en) 2000-11-28
WO1997047732A2 (en) 1997-12-18
EP0975355A2 (en) 2000-02-02
AU3804397A (en) 1998-01-07

Similar Documents

Publication Publication Date Title
WO1997047732A3 (en) Hexameric fusion proteins and uses therefor
EP2128260A3 (en) Modified TGF-beta superfamily proteins
DK0692025T3 (en) Yeast cells designed to produce surrogates for proteins in the pheromone system, and uses thereof
EP0921395A3 (en) Assays for measurement of protein fragments in biological media
WO2000023564A3 (en) Protein design automation for protein libraries
WO1999066054A3 (en) Erythropoietin analog-human serum albumin fusion protein
EP0962467A4 (en) ANTIBODIES AGAINST HUMAN PARATHORMON RELATED PEPTIDES
WO2001018244A3 (en) Selection system
WO2003029458A3 (en) Method for producing protein libraries and for selecting proteins from said libraries
AU3667399A (en) Monoclonal antibodies specific for anthrax spores and peptides derived from the antibodies thereof
AU2661199A (en) Mammalian receptor proteins; related reagents and methods
WO1999020747A3 (en) HUMAN CHECKPOINT KINASE, hCDS1, COMPOSITIONS AND METHODS
AU1686395A (en) (deltex) proteins, nucleic acids, and antibodies, and related methods and compositions
AU1448295A (en) Assay employing both protein and antibody
WO2000015798A3 (en) Mammalian transforming growth factor beta - 9 (ztgfss9)
WO1998057983A3 (en) Mammalian neuro-growth factor like protein
CA2173102A1 (en) Dna sequence coding for a bmp receptor
WO1997045746A3 (en) Prion protein binding proteins and uses thereof
AU4553296A (en) Method and reagent for the specific determination of LDL in serum samples
WO2001044809A3 (en) Evaluation of biological agents in living target cells
AU1971799A (en) Peptide epitopes recognised by antifilaggrin autoantibodies in serum from rheumatoid arthritis patients
WO2000018909A3 (en) NUCLEIC ACIDS AND PROTEINS FROM $i(CENARCHAEUM SYMBIOSUM)
AU5137698A (en) Novel dna, novel protein, and novel antibody
AU6443494A (en) An endogenous taxol-like substance in human serum, monoclonal antibodies directed thereto, and methods of assaying therefor
AU1599299A (en) Methods and reagents for the utilization of sap family member proteins, novel signal transduction regulators

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU BB BG BR CA CN CZ EE GE GH HU IL IS JP KG KP KR LK LR LT LV MD MG MK MN MX NO NZ PL RO SG SI SK TR TT UA US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2257861

Country of ref document: CA

Ref country code: CA

Ref document number: 2257861

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997935005

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997935005

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997935005

Country of ref document: EP